The current status of ponatinib in the treatment of chronic myeloid leukemia

Clinical Advances in Hematology and Oncology

Volumn 12, Issue 5, 2014, Pages 329-331

  Deininger, Michael ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; LENALIDOMIDE; NILOTINIB; PONATINIB; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; PYRIDAZINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER PALLIATIVE THERAPY; CEREBROVASCULAR ACCIDENT; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DISEASE CONTROL; DRUG APPROVAL; DRUG BINDING; DRUG EFFICACY; DRUG INDUCED DISEASE; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HEART INFARCTION; HUMAN; MYELODYSPLASTIC SYNDROME; NOTE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHILADELPHIA 1 CHROMOSOME; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;

ANTINEOPLASTIC AGENTS; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PYRIDAZINES;

EID: 84901830557     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (4)

1. Baccarani M, Deininger MW, Rosti G et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872-884.
2. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367(22):2075-2088.
3. Cortes JE, Kim DW, Pinilla-Ibarz J, et al; PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783-1796.
4. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5)401-412.